Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

AGI-1067 as a Novel Antidiabetic Agent Evaluation Study

NCT00525577 is registered in ClinicalTrials.gov with AtheroGenics as lead sponsor.

NCT NCT00525577
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00525577 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
AGI-1067 as a Novel Antidiabetic Agent Evaluation Study
Lead sponsor
AtheroGenics
Phase
Phase 2/3
Overall status
Unknown status
Start date
August 31, 2007
Completion date
September 30, 2008
Enrollment
1,012 (estimated)
Sites
90

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes